CANCERS BRONCHIQUES A PETITES CELLULES

CANCERS BRONCHIQUES A PETITES CELLULES
ESSAIS TESTANT L’ASSOCIATION CISPLATINE PLUS ETOPOSIDE

Référence	chimiothérapie	stade	nb pts	RO %	p	SM	p
Maksymiuk, 1994	1. CDDP 30 – VP16 130 iv J1-3		136	87	NS	14,6 m	0,001
	2. VP16 130- CDDP 30 iv J1-3		138	82		11,1 m
	3. VP16 130 (IC24h)- CDDP 30 iv J1-		139	83		13 m
	4. VP16 130 (IC24h) x3 -CDDP 45(IC24h) x2		139	86		11,4 m
Sundstrom, 2002	1. CDDP 75 – VP16	Tous	218			10,2 m
		ML	105			14,5 m
		ME	113			8,4 m
	2. CPA – épirubicine – VCR	Tous	218			7,8 m	S
		ML	109			9,7 m	S
		ME	109			6,5 m	NS
Thatcher, 2005	1. Ifo (5) + Carbo (300) + VP16 (120 x 3) + VCR (1 J14)	Bon PS	203	83	NS	15,6 m	0,005
Thatcher, 2005	2. CPA-ADR-VP16 ou CDDP-VP16	Bon PS	199	80	NS	11,6 m	0,005

Références

(1) Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA et al. Sequencing and schedule effects of cisplatin plus etoposide in small- cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994; 12(1):70-76.

(2) Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up. J Clin Oncol 2002; 20(24):4665-4672.

(3) Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005; 23(33):8371-8379.

(4) Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008 Aug 5;99(3):442-7.